Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists

Supportive Care in Cancer

Volumn 19, Issue 12, 2011, Pages 1983-1990

  Majem, Margarita ^a   Moreno, Ma Estela ^a   Calvo, Núria ^a   Feliu, Anna ^a   Pérez, Javier ^a   Mangues, Ma Antonia ^a   Barnadas, Agustí ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Antiemetics; Chemotherapy induced emesis; Chemotherapy induced Nausea; Observed incidence; Perception

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; DEXAMETHASONE; GRANISETRON; NEUROKININ 1 RECEPTOR;

ACCURACY; ADULT; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; ESOPHAGUS CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA AND VOMITING; NURSE; OBSERVATIONAL STUDY; PATIENT; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SARCOMA; STOMACH CANCER;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NURSES; PATIENTS; PHYSICIANS; PROSPECTIVE STUDIES; RECEPTORS, NEUROKININ-1; SELF REPORT; SPAIN; VOMITING;

EID: 83555163918     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-1042-3     Document Type: Article

References (26)

1. A Coates S Abraham SB Kaye T Sowerbutts C Frewin RM Fox MH Tattersall 1983 On the receiving end-patient perception of the side-effects of cancer chemotherapy Eur J Cancer Clin Oncol 19 203 208 6681766 10.1016/0277-5379(83) 90418-2 1:STN:280:DyaL3s7jtFyitw%3D%3D (Pubitemid 13155858)
2. A Coates CF Dillenbeck DR McNeil SB Kaye K Sims RM Fox RL Woods GW Milton J Solomon MH Tattersall 1983 On the receiving end-II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer Clin Oncol 19 1633 1637 6315445 10.1016/0277-5379(83)90096-2 1:STN:280:DyaL2c%2Flsl2htQ%3D%3D
3. GM Decker ES DeMeyer DL Kisko 2006 Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy J Support Oncol 4 35-41 52
4. A Erazo Valle T Wisniewski JI Figueroa Vadillo TA Burke R Martinez Corona 2006 Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed Curr Med Res Opin 22 2403 2410 17257454 10.1185/030079906X154033 (Pubitemid 46048355)
5. A Fabi M Barduagni S Lauro L Portalone M Mauri F Marinis C Narduzzi G Tonini M Giampaolo U Pacetti F Paoloni F Cognetti 2003 Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study Support Care Cancer 11 156 161 12618925 (Pubitemid 36733809)
6. R Gralla M Lichinitser S Van Der Vegt H Sleeboom J Mezger C Peschel G Tonini R Labianca A Macciocchi M Aapro 2003 Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 1570 1577 14504060 10.1093/annonc/mdg417 1:STN:280:DC%2BD3svktlKitQ%3D%3D (Pubitemid 37304615)
7. RJ Gralla LM Itri SE Pisko AE Squillante DP Kelsen DW Braun Jr LA Bordin TJ Braun CW Young 1981 Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting N Engl J Med 305 905 909 7024807 10.1056/NEJM198110153051601 1:STN:280:DyaL38%2FhtlCrsQ%3D%3D (Pubitemid 11014529)
8. AM Griffin PN Butow AS Coates AM Childs PM Ellis SM Dunn MH Tattersall 1996 On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993 Ann Oncol 7 189 195 8777177 1:STN:280:DyaK283mt1ejtw%3D%3D (Pubitemid 26094884)
9. SM Grunberg RR Deuson P Mavros O Geling M Hansen G Cruciani B Daniele G De Pouvourville EB Rubenstein G Daugaard 2004 Incidence of chemotherapy-induced nausea and emesis after modern antiemetics Cancer 100 2261 2268 15139073 10.1002/cncr.20230 (Pubitemid 38580348)
10. SM Grunberg PJ Hesketh 1993 Control of chemotherapy-induced emesis N Engl J Med 329 1790 1796 8232489 10.1056/NEJM199312093292408 1:STN:280: DyaK2c%2FltVSltg%3D%3D (Pubitemid 23355554)
11. Hesketh PJ, Aapro M, Street JC, Carides AD (2009) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy Support Care Cancer
12. PJ Hesketh SM Grunberg RJ Gralla DG Warr F Roila R de Wit SP Chawla AD Carides J Ianus ME Elmer JK Evans K Beck S Reines KJ Horgan 2003 The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Grou J Clin Oncol 21 4112 4119 14559886 10.1200/JCO.2003.01.095 1:CAS:528:DC%2BD2cXpsVajtr0%3D (Pubitemid 46606178)
13. PJ Hesketh MG Kris SM Grunberg T Beck JD Hainsworth G Harker MS Aapro D Gandara CM Lindley 1997 Proposal for classifying the acute emetogenicity of cancer chemotherapy J Clin Oncol 15 103 109 8996130 1:STN:280: DyaK2s7kvFehsA%3D%3D (Pubitemid 27020563)
14. JT Hickok JA Roscoe GR Morrow DK King JN Atkins TR Fitch 2003 Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community Cancer 97 2880 2886 12767103 10.1002/cncr.11408 1:CAS:528:DC%2BD3sXkslWrsLg%3D (Pubitemid 36605158)
15. MG Kris PJ Hesketh MR Somerfield P Feyer R Clark-Snow JM Koeller GR Morrow LW Chinnery MJ Chesney RJ Gralla SM Grunberg 2006 American Society of Clinical Oncology guideline for antiemetics in oncology: update J Clin Oncol 24 2932 2947 16717289 10.1200/JCO.2006.06.9591 1:CAS:528:DC%2BD28XntV2gs7k%3D (Pubitemid 46630595)
16. CT Liau NM Chu HE Liu R Deuson J Lien JS Chen 2005 Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes Support Care Cancer 13 277 286 15770489 10.1007/s00520-005-0788-5 (Pubitemid 40674832)
17. AR Martin AD Carides JD Pearson K Horgan M Elmer C Schmidt B Cai SP Chawla SM Grunberg 2003 Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant Eur J Cancer 39 1395 1401 12826042 10.1016/S0959-8049(03)00299-5 1:CAS:528:DC%2BD3sXkvVSqu7Y%3D (Pubitemid 36773782)
18. AR Martin JD Pearson B Cai M Elmer K Horgan C Lindley 2003 Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall Support Care Cancer 11 8 522 527 12827483 10.1007/s00520-003-0482-4 1:STN:280:DC%2BD3szntV2isA%3D%3D (Pubitemid 36994435)
19. GR Morrow J Lindke PM Black 1991 Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics J Pain Symptom Manage 6 215 223 2030296 10.1016/0885-3924(91) 90011-R 1:STN:280:DyaK3M3jtFOhug%3D%3D
20. National Comprehensive Cancer Network (2010) NCCN Clinical Practice Guidelines in oncology: antiemesis Version 2.2010
21. RM Navari RR Reinhardt RJ Gralla MG Kris PJ Hesketh A Khojasteh H Kindler TH Grote K Pendergrass SM Grunberg AD Carides BJ Gertz 1999 Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754, 030 Antiemetic Trials Group N Engl J Med 340 190 195 9917226 10.1056/NEJM199901213400304 1:CAS:528:DyaK1MXhtV2gtrY%3D (Pubitemid 29063215)
22. S Newell RW Sanson-Fisher A Girgis A Bonaventura 1998 How well do medical oncologists' perceptions reflect their patients' reported physical and psychosocial problems? Data from a survey of five oncologists Cancer 83 1640 1651 9781960 10.1002/(SICI)1097-0142(19981015)83:8<1640::AID-CNCR21>3.0. CO;2-# 1:STN:280:DyaK1cvltlahsw%3D%3D (Pubitemid 28465484)
23. F Roila PJ Hesketh J Herrstedt 2006 Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference Ann Oncol 17 20 28 16314401 10.1093/annonc/ mdj936 1:STN:280:DC%2BD28%2FkvVKmtQ%3D%3D (Pubitemid 43033835)
24. DG Warr SM Grunberg RJ Gralla PJ Hesketh F Roila R Wit AD Carides A Taylor JK Evans KJ Horgan 2005 The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials Eur J Cancer 41 1278 1285 15939263 10.1016/j.ejca.2005.01.024 1:CAS:528:DC%2BD2MXltFCktrk%3D (Pubitemid 40813003)
25. DG Warr PJ Hesketh RJ Gralla HB Muss J Herrstedt PD Eisenberg H Raftopoulos SM Grunberg M Gabriel A Rodgers N Bohidar G Klinger CM Hustad KJ Horgan F Skobieranda 2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J Clin Oncol 23 2822 2830 15837996 10.1200/JCO.2005.09.050 1:CAS:528:DC%2BD2MXktleqt74%3D (Pubitemid 46179473)
26. PM Wilcox JH Fetting KM Nettesheim MD Abeloff 1982 Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma Cancer Treat Rep 66 1601 1604 7049385 1:STN:280:DyaL383lvFWhtg%3D%3D (Pubitemid 12046117)